BIO International Convention
When: 22-25 June, 2026
Where: San Diego
95+
start-ups supported
24
exits to date
£3.55bn
raised by our portfolio to date
What we offer
| Seed investment | Start-up support | Scientific expertise | Expert network |
| Our Seed Fund has provided early-stage funding to 22 exciting new ventures so far, and our portfolio continues to grow with several ground breaking opportunities in stealth. | Our expert teams guide researchers in developing their promising discoveries - from entrepreneurial training, advice and funding through to seed investment and commercial support for company formation and scaling up. | We leverage our drug discovery and development expertise in partnerships with researchers and industry to identify and advance novel approaches with the potential to deliver the next generation of cancer medicines. | We have unparalleled access to a global network of researchers, clinicians and partners allowing us to call on world-leading experts to validate translational potential and inform our investment decisions. |
Join our Cancer Impact Club
Investor news
Our Cancer Impact Club is a community of business builders whose philanthropy, expertise and networks will multiply our impact on early-stage cancer ventures. It comprises entrepreneurs and leaders from private equity, venture capital, and associated companies and will bring together up to 50 members to raise £5m to help double our Seed Fund’s impact.
Our Investor Networking Breakfast series
These invite-only events showcase innovative companies from across our start-up portfolio that are reaching major milestones towards patient impact, bringing together like-minded oncology investors and innovators for networking and insights.
Get in touch with our team to learn when our next Investor Networking Breakfast is taking place.
Contact us
Our start-up portfolio
We've built an incredible assembly line for start-up companies to bring early-stage technologies out of the research lab and translate them into patient benefit.
To date, we've played a role in the creation of 79 start-ups, with our portfolio of existing companies raising in excess of £3bn in total capital.
Ventures team
Our Ventures team have a long-standing track record of sourcing, evaluating and creating start-ups. They manage the Seed Fund work alongside an independent investment committee to review applications.
Trogenix close £70m Series A funding round
Portfolio news
This funding round enables the advancement of their robust pipeline of potentially curative cancer therapies towards the clinic.
We’re proud to have made our largest investment to date to support Trogenix’s clinical pipeline – including programmes in glioblastoma and colorectal cancer liver metastases – and to back a team aiming to reshape outcomes in areas of huge unmet need.
How we partner with investors
We're keen to connect with seed and series A-focused funds to create and grow new companies offering unique early-stage investment opportunities.
Our Seed Fund investments are catalytic, with Cancer Research Horizons considered a validating investor by like-minded early-stage investors. An important impact measure for the fund is to leverage third-party capital alongside our own investments.
Join our expert network
Our world-class expert network, drawn from our extensive research community and partners, comprises leading business, scientific, clinical, investment, and industry experts across the oncology sector.
Their unrivalled experience and expertise help empower our researchers and founding teams, and maximise the success of our venture, licensing, and partnership opportunities.
Interested in investing in world-leading cancer research?
We're seeking investors and co-investors across our portfolio.